Teleflex Incorporated: Recent Developments In Urology & Bladder Management Portfolio Are Very Encouraging! 

Teleflex Incorporated reported its fourth-quarter and full-year 2024 earnings, highlighting both positive performances and challenges. The company’s fourth-quarter revenues reached $795.4 million, marking a year over-year increase of 2.8% on a GAAP basis and a 3.2% increase on an adjusted constant currency basis. This growth was largely driven by the strong performance of the Interventional and Surgical business segments, which recorded adjusted constant currency growth rates of 18.7% and 12.3%, respectively. However, the quarter fell short of revenue expectations by $10.2 million, attributed partly to lower hospitalizations due to flu and COVID-19 impacts on the Vascular business unit and softer Interventional Urology revenues.